Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
-- Presentation of 24-week data from the second cohort and an update from first cohort of patients in the OPTIC trial at Angiogenesis Meeting on Saturday, February 8, 2010 at 2:28 pm EST -- -- Company...
-
•The new data show PAS-nomacopan (the long acting form of Akari’s lead drug, nomacopan) significantly reduced VEGF levels and retinal inflammation, both of which are associated with permanent damage...
-
WATERTOWN, Mass., Jan. 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic...
-
·Application is being reviewed under FDA’s Real-Time Oncology Review pilot programme Basel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental...
-
Selbyville, Delaware, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Global Market Insights, Inc. has recently added a new report on Lasik Eye Surgery Devices Market which estimates the global market valuation...
-
Basel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy...
-
–Encouraging preliminary signs of biologic activity and a favorable safety profile are outcomes that are clinically relevant to patients – Enrollment ongoing in additional dose groups, which will...
-
Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMANo treatment related safety findings leading to withdrawal seen in any...
-
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...
-
LAUSANNE, Switzerland, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...